{"name":"OncoMed Pharmaceuticals, Inc.","slug":"oncomed-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing \"targeted antibodies against cancer stem cells\". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. In April 2019 the company was acquired by Mereo BioPharma and delisted from the Nasdaq.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":38154000,"revenueGrowth":84.9,"grossMargin":0,"rdSpend":34443000,"netIncome":-8101000,"cash":65078000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"OMP-131R10","genericName":"OMP-131R10","slug":"omp-131r10","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"OMP-131R10","genericName":"OMP-131R10","slug":"omp-131r10","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNa3V4ZWxLV1VDLXptT25vR0U2OHJ5el92RFFFUkpvN2xMSDlSWW9rVHRQQlFVekYxdDAyRnJOVU8wa2VxODI3eUpQSkpleTVQVkZ5Tlp1VlZMd1RnSXJPcFVfazliN0s4azZkNl9lUWZ6T0RuLWJOTkpZdnMtSngxdDdxMl9FSHBXbjF0TW1TOUQ5VzJYWDRuQk1oSEVMYVNLYzNvSQ?oc=5","date":"2026-02-02","type":"pipeline","source":"Contract Pharma","summary":"Alterome Therapeutics Appoints Leonardo Faoro as New CMO - Contract Pharma","headline":"Alterome Therapeutics Appoints Leonardo Faoro as New CMO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPX3dIaEVIVFpvV1Z4ek5FdldreDJJc2dKOF9fOUJLcjJvZHNaRDJVRGM3Z3NkaVJpT0xIOUxUVjJmaERUZmxVcldqaEc0Y2NVVE9aLU9WWUFzZmNPLWNYR3VuUmJ3N1Z1UHppNzRha0ZCVXZ5Q0dlVnZWcDZIVHdvSGhHblIzXzBtSnpMT284R2g3NjhFNnZmN2ZPSjlWc0RXMjZEQUd3cGJnXzQ?oc=5","date":"2023-05-19","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Gilead finds Christi Shaw replacement, taps Roche exec to fly Kite - Fierce Biotech","headline":"Chutes & Ladders—Gilead finds Christi Shaw replacement, taps Roche exec to fly Kite","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOLWtIX0l5QlQ5Wkx4dEFsdzFmZjB5Ri04NlV5elNRQVVJdjRsR3ctN0xUNjdzNWp6ZEVpUm1Xd1FHT2k0MzUtdC13b19YMDRKWXV5VzU4YWtMZGxiSGNLSFJrYXN3b1lzRlFmMDJncUNvdXp1dEdYYkM5OHdwT2xxeE9zVDJCZW9KYU56d0M4RVJwOEpwbHU1MTRDcThkM3F6U1hvQg?oc=5","date":"2021-11-18","type":"trial","source":"BioWorld News","summary":"Mereo heads into phase III with drug for brittle bone disease - BioWorld News","headline":"Mereo heads into phase III with drug for brittle bone disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxPM241ZGtPQmxrSlA3SV9UbjUtb05sbmNLOGg2TEo2aDVsVU9OX0oxUEJxSnhVOFZuLTF2b3ZUMUVZSTc4MWV4ekxhTExzVC13aDZaZ3dNYjgwVFh5bm10emxENmZ2UWZpckQ1bUJlUWYybzltV0taXzA5R1RxVERRclJsTlI1MlhxRFgyTk9sYnM0dndJM3FiMVdJcFM3LThqUnZSb1JNR1dnOXYyUFBaQ1ZEWEYtbFBKdG1nUDgwTzdGcG43Uk0yb3NVekxteEFGbFM4WmdJQkR4UFVDcjVBRFFyaG1sWTRCcFRyWS1MaW4zeWJXMEdZOFUwejVWLTZ6RGE2RjB4aEtJWDNDVk82ckVGWHFoS1lV?oc=5","date":"2019-04-23","type":"pipeline","source":"GlobeNewswire","summary":"Mereo BioPharma Group plc (\"Mereo\" or the \"Company\" or the - GlobeNewswire","headline":"Mereo BioPharma Group plc (\"Mereo\" or the \"Company\" or the","sentiment":"neutral"},{"date":"2019-04-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2019-04-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNWE5NNXE5M3dCd1RvcVBEa1dudldUbGt4SVlIcnE2Y1FsVkM1YUgtaFh0Ny0yd3BuY0lNdkpkVkVreFBXUlFwRjZDZkR2Z2pYZmxrYkRicy15Ri1qVXhOWWhmOUMtSUVBYVl5QzFpcmI4X3hTSW16UXpkT1ZUanNQcXFYNjlpNmdQbTBZWWRKa2tyUQ?oc=5","date":"2018-12-06","type":"deal","source":"pharmaphorum","summary":"After delayed IPO, Mereo gets US listing via OncoMed merger - pharmaphorum","headline":"After delayed IPO, Mereo gets US listing via OncoMed merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPYUhtdlRJN05uQVlVM1IweWN3clhVdFF3Vkg1bGhpbTJBcGtXNjA0dF9UMmNfYzFfNVF6aE4xeWV4bk9nUmc5TnNmajQtd1NuTnhERzdnRVJIWHI0YU1rVGpPdGo0c2dSMDhwOGozcFBVN1FLNTl4bkxiSHhMMlVmS25CSDl6Nkxqb1o2RVRZaFNpSTdicVF3UVZDclRqWl9wOXZla1Nmd2R1cG12X1ZkVldKVHQwa1hY?oc=5","date":"2018-05-29","type":"trial","source":"Clinical Leader","summary":"The Evolving Reimbursement Landscape — Considerations For Clinical Trial Design - Clinical Leader","headline":"The Evolving Reimbursement Landscape — Considerations For Clinical Trial Design","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOcXpFNnVmMy10YVA0cDBvNXBTbnprVmlaWDJlMU1sbzZCZFd0QlVhTkxvRVdwMXR2N0hEUzFEX3BJZmYtRnVfZVYtbVV0bTdodXloRWtUNUxqNXZjaHY4S2p1WWhUMUVfYkxod1FWdG9XMm1VVGZGWWRUQXBSMEMydzREa1FXVjYtMVdfQVpB?oc=5","date":"2017-04-17","type":"pipeline","source":"BioPharma Dive","summary":"OncoMed hit with another mid-stage failure - BioPharma Dive","headline":"OncoMed hit with another mid-stage failure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNYk5GYVh6WHcxaWpOcTBNZHR1aVVhWTUzQ1k0Y09IUlZqNWM4SThzMExYcGhtWXd1V1dMNXlVTV9jb21fZUxpQmxEY2oxeW01Ukk0V1RaZUs4clpZR0dueGpTdEpXSU5qS3JjZFc5YU11T2U0TW1lMWp2N1g1Qmw3VThWUGQ2bXZaaDU0RDBrcDB1Z3p0TXpoLXJ6REJ5Zw?oc=5","date":"2017-04-10","type":"pipeline","source":"The Motley Fool","summary":"Why Oncomed Pharmaceuticals Inc. Got Slaughtered Today - The Motley Fool","headline":"Why Oncomed Pharmaceuticals Inc. Got Slaughtered Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNel9wdDk3MjA0SGwxbmZkWmhpUFN0S3RldVliak1rREo5aW5heVZXdnp3LWpWZlgyMzFQcUxubDNBRFgtTXMyRVJjYTJsU2pNSzNnMk9FRVRaY3VnSkVrVjNLdldCQkRlaTY0ZGJrN1F6UUtlOW5HeURCbm9sM3FQN2VnZGROdw?oc=5","date":"2014-06-13","type":"trial","source":"drugdiscoverytrends.com","summary":"OncoMed Halts Wnt Pathway Inhibitor Trials - drugdiscoverytrends.com","headline":"OncoMed Halts Wnt Pathway Inhibitor Trials","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5uT2NhXzFOYzh2TE11bndRVW45LUM2NS1kZDRHc1hJSVljb3UxTVBtS0M1ZHRycjdodUFjYXlUVThxMDFWRVBMOUZxRWZmTTktTmstbkxpbVgwZDVGdFR2UndVdTBhWVR0WThaa0pyR0VxX3lNamc?oc=5","date":"2014-03-18","type":"pipeline","source":"RTTNews","summary":"OncoMed Pharma Loss Widens - RTTNews","headline":"OncoMed Pharma Loss Widens","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxObngtYmZWSExtd2QycEd4aHliQm5IVUU1Wk96Mm1zLVY3VzdORVowRzBjSzA0SVFIMGczMzd0ZE5oaHEtdEtKSm0wWTh2cXFhUHo2cTA5MFU1cTUzU2pmUWdsMHJmZlBzTU9zbFl3Ymo5dVZ6dTlRU09CS0RUOE1YeWZUNXEyNjgxSFhEMHFrMWpiUDM4MFNDbTJja0JBeEExNGZyVGxndnFYNjJBZEJpT1Uwakp4UnZibDIzdFRMT0g4V05hNmNTeA?oc=5","date":"2014-02-10","type":"pipeline","source":"The University of Rhode Island","summary":"Paul Hasting '84, CEO of OncoMed Pharmaceuticals, Inc. to ring the Closing NASDAQ Bell Today - The University of Rhode Island","headline":"Paul Hasting '84, CEO of OncoMed Pharmaceuticals, Inc. to ring the Closing NASDAQ Bell Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPLWhIc0RGVGlOS3pIZnBhQTZBcGRXeHdDR2RxdVlZOWxWMUdmTFJscnEtSWNiSjNmNGkydV80ZlZpY3B6YkZlRVVZcHhJOXdxeUl3TmlQVXlGaTNHVEppRlQzSjFpcFRNSW92cUN5MkNOSml3VWpDc3RmY2dGR0pLbnFLbnZMUWo1aEFzZ3k0RHJpVmRhSHZETGdqdFVORmVMSHc?oc=5","date":"2010-06-17","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Bayer Pays OncoMed $40M to Develop Drugs Targeting Cancer Stem Cells - Genetic Engineering and Biotechnology News","headline":"Bayer Pays OncoMed $40M to Develop Drugs Targeting Cancer Stem Cells","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":38154000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":38154000,"period":"2017-12-31"},{"value":20640000,"period":"2017-12-31"},{"value":5106000,"period":"2017-09-30"},{"value":6195000,"period":"2017-06-30"},{"value":6213000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":34443000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-8101000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":65078000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}